Enlivex Therapeutics Ltd
NASDAQ:ENLV

Watchlist Manager
Enlivex Therapeutics Ltd Logo
Enlivex Therapeutics Ltd
NASDAQ:ENLV
Watchlist
Price: 1.23 USD -0.81%
Market Cap: 27m USD
Have any thoughts about
Enlivex Therapeutics Ltd?
Write Note

Enlivex Therapeutics Ltd
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Enlivex Therapeutics Ltd
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
Enlivex Therapeutics Ltd
NASDAQ:ENLV
Other Long-Term Assets
$406k
CAGR 3-Years
65%
CAGR 5-Years
42%
CAGR 10-Years
N/A
Collplant Biotechnologies Ltd
NASDAQ:CLGN
Other Long-Term Assets
$57k
CAGR 3-Years
-32%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Kamada Ltd
NASDAQ:KMDA
Other Long-Term Assets
$143.2m
CAGR 3-Years
157%
CAGR 5-Years
146%
CAGR 10-Years
107%
Urogen Pharma Ltd
NASDAQ:URGN
Other Long-Term Assets
$545k
CAGR 3-Years
-35%
CAGR 5-Years
40%
CAGR 10-Years
N/A
B
Bonus Biogroup Ltd
TASE:BONS
Other Long-Term Assets
â‚Ş374k
CAGR 3-Years
-7%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Pluri Inc
NASDAQ:PLUR
Other Long-Term Assets
$1.2m
CAGR 3-Years
19%
CAGR 5-Years
11%
CAGR 10-Years
5%
No Stocks Found

Enlivex Therapeutics Ltd
Glance View

Market Cap
25.7m USD
Industry
Biotechnology

Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

ENLV Intrinsic Value
1.18 USD
Overvaluation 4%
Intrinsic Value
Price

See Also

What is Enlivex Therapeutics Ltd's Other Long-Term Assets?
Other Long-Term Assets
406k USD

Based on the financial report for Jun 30, 2024, Enlivex Therapeutics Ltd's Other Long-Term Assets amounts to 406k USD.

What is Enlivex Therapeutics Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
42%

Over the last year, the Other Long-Term Assets growth was -95%. The average annual Other Long-Term Assets growth rates for Enlivex Therapeutics Ltd have been 65% over the past three years , 42% over the past five years .

Back to Top